Th2 differentiation inhibitors
US7008954B1 · kind B1 · utility
9Cited by
3References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 14, 2000 |
| Grant date | Mar 7, 2006 |
| Priority date | — |
| Expiry date | Oct 13, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C217/80
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a pharmaceutical composition for use as a Th2 differentiation inhibitor comprising a compound represented by Formula (I): wherein each of ring A, ring B and ring C is an aromatic carbocyclic ring, a heterocyclic ring and the like, X is a single bond, —O—, —CH2—, —NH—, —SO— and the like, Y is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl and the like, each of V1 and V2 is a single bond, —O—, —NH—, —OCH2— and the like, a prodrug, pharmaceutically acceptable salt or solvate thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.